Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer

Sugarbaker, Paul H.; Speeten, Kurt Van der; Stuart, O. Anthony

doi:10.4251/wjgo.v2.i1.19

Cited by 54 publications

(24 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMC and Oxali are the traditional choices for management of CRC with PC as these reagents have large molecular weights, similar tissue penetrance, and work independently of the cell cycle. Ultimately, their large size allows for highly concentrated preparations to be given intraperitoneal and limiting systemic absorption and toxicities 24‐26 . MMC and Oxali have also been demonstrated to be more effective as hyperthermic preparations 26,27 .…”

Section: Discussionmentioning

confidence: 99%

Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer

Woeste

Philips

Egger

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Peritoneal carcinomatosis of colorectal adenocarcinoma (CRC) origin is common and is the second-most frequent cause of death in colorectal cancer. There is survival benefit to surgical resection plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with metastatic CRC. However, there remains controversy between oxaliplatin (Oxali) and mitomycin C (MMC), as the agent of choice. Methods: A review of our 285 patients prospective HIPEC database from July 2007 to May 2018 identified 48 patients who underwent cytoreductive surgery plus HIPEC with MMC or Oxali. Patients were stratified based on preoperative and postoperative peritoneal cancer indices (PCI). The primary outcomes of survival and progression-free survival were compared.Results: Type of HIPEC chemotherapy was not found to be predictive of overall survival. Preoperative PCI (P = .04), preoperative response to chemotherapy (P = .0001), and postoperative PCI (P = .05) were predictive for overall survival. Conclusions: MMC or Oxali based HIPEC chemotherapy are both safe and effective for the management of peritoneal only metastatic CRC. Both perfusion therapies should be considered with all patients receiving modern induction chemotherapy. K E Y W O R D S carcinomatosis, colorectal cancer, HIPEC, hyperthermic intraperitoneal chemotherapy, mitomycin C, oxaliplatin

show abstract

Section: Discussionmentioning

confidence: 99%

Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer

Woeste

Philips

Egger

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The Ziegler-Nichols controller's transfer function is shown in (9 where k CZN is the controller's gain, T IZN is the integral time constant and T DZN is the derivative time constant, obtained using the Ziegler-Nichols design method.…”

Section: B Ziegler-nichols Design Methodsmentioning

confidence: 99%

“…Nowadays cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) proves to be a promising therapeutic solution for patients suffering from PC [3]- [5]. HIPEC requires the spread of cytostatic drugs during the surgical intervention at high temperatures (41-43˚C), by means of a device, within 60-120 minutes [6]- [9]. Currently there are some HIPEC devices based on different techniques [10]- [12].…”

Section: Introductionmentioning

confidence: 99%

Measured signal identification and temperature controller design for a HIPEC device

Clitan

Mureşan

Moga

et al. 2015

2015 38th International Conference on Telecommunications and Signal Processing (TSP)

View full text Add to dashboard Cite

Peritoneal Carcinomatosis (PC) is an abdominal cancer for which cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) proved to be a promising treatment. HIPEC requires the intraperitoneal spread of cytostatic solution at high temperatures (41-43˚C) accomplished within 60-120 minutes, during surgical interventions. This paper presents the heating system's identification, by using a graphical fitting method on a temperature measured signal, for a HIPEC device intended to be developed. Also the design of two PID temperature controllers is presented, using the Strejc design method and the Ziegler-Nichols method. The two feedback control structures are compared via simulation, based on their step response signals and their overall performances.

show abstract

“…The peritoneal-plasma barrier (PPB) consists of a monolayer of mesothelial tissue, which account for a total thickness of 90 μm. The connective tissue layers include interstitial cells and a matrix of collagen, hyaluron, and proteoglycans (15). The PPB, which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity, results in a large exposure of small cancer nodules on abdominal and pelvic surfaces.…”

Section: Review Articlementioning

confidence: 99%

Intraperitoneal chemotherapy for locally advanced gastric cancer to prevent and treat peritoneal carcinomatosis

Liang

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the leading causes of cancer death in both sexes in the world. The overall survival (OS) of GC patients is still unsatisfactory. The peritoneal dissemination is the most common type of recurrence in advanced GC. The rationale for administering chemotherapeutic drugs directly into peritoneal cavity is supported by the relative transport barrier that is formed by the tissue surrounding the peritoneal space. Intraperitoneal (IP) chemotherapy with taxanes is safe and feasible. Further randomized phase III clinical trials are needed to validate IP chemotherapy with taxanes for peritoneal carcinomatosis (PC) from GC. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) used as prophylaxis against peritoneal recurrence in patients with high risk GC is safe, significantly improves the survival and reduces the risk of peritoneal recurrence. A drug delivery system with anticancer drugs seem to be have a pharmacokinetic advantage but further randomized clinical trials are needed to validate its effect.

show abstract

Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer

Abstract: Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer.

Cited by 54 publications

References 84 publications

Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer

Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer

Measured signal identification and temperature controller design for a HIPEC device

Intraperitoneal chemotherapy for locally advanced gastric cancer to prevent and treat peritoneal carcinomatosis

Contact Info

Product

Resources

About